EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nanomedicine for Treating Major Brain Diseases: Advances and Future Directions

Girisha Sagar, Barnabas Wilson iD, Geetha Kannoth Mukundan, Kalpana Divekar, Josephine Leno Jenita

Molecular Pharmaceutics · 04.08.2025 · 22 (8) · 4413-4434

DOI: 10.1021/acs.molpharmaceut.5c00277 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 30.06.2025. Verfasst von Girisha Sagar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda Sagar University, Devarakaggalahalli, Harohalli, Kanakapura Road, Bengalur…. Hauptthemen laut MEDLINE: Nanomedicine, Brain Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 178 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traditional drug delivery systems lack target specificity. Various macromolecules, which are useful to treat central nervous system (CNS) diseases, have failed in clinical trials. This is because the molecules fail to cross the blood-brain barrier (BBB) effectively. The diseases of the brain are a major cause of disability and death. Various brain diseases affect 3.4 billion people worldwide. Nanomedicine, the medical application of nanotechnology for the diagnosis and treatment of diseases, improves drugs' solubility, stability, bioavailability, safety, and therapeutic efficacy. Site-specific ligand conjugated nanomedicine increases the target-specificity of nanomedicine toward specific receptors or determinants and delivers the drugs to the target organ. Nanomedicine provides better patient care while minimizing side effects and treatment cost. Further, it has the ability to change the traditional way of diagnosing and treating diseases. This review discusses recent advances in the usefulness of nanomedicine to treat major brain diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and stroke. The article also addresses the challenges in the development of nanoformulation and associated nanotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanomedicineBrain DiseasesHumansBlood-Brain BarrierDrug Delivery SystemsAnimalsNanoparticlesAlzheimer DiseaseParkinson Disease

Stichwörter der Autor:innen

Alzheimer’s diseaseParkinson’s diseaseblood-brain barriernanomedicinestroke

Autor:innen und Institutionen

  • Department of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda Sagar University, Devarakaggalahalli, Harohalli, Kanakapura Road, Bengaluru 562112, Karnataka, India.
  • Department of Pharmacology, College of Pharmaceutical Sciences, Dayananda Sagar University, Devarakaggalahalli, Harohalli, Kanakapura Road, Bengaluru 562112, Karnataka, India.
  • Department of Pharmaceutical Chemistry, College of Pharmaceutical Sciences, Dayananda Sagar University, Devarakaggalahalli, Harohalli, Kanakapura Road, Bengaluru 562112, Karnataka, India.

ORCID-Profile: Barnabas Wilson

Zitieren

APA

Sagar, G., Wilson, B., Kannoth Mukundan, G., Divekar, K., & Jenita, J. L. (2025). Nanomedicine for Treating Major Brain Diseases: Advances and Future Directions. Molecular Pharmaceutics, 22(8), 4413-4434. https://doi.org/10.1021/acs.molpharmaceut.5c00277

Vancouver

Sagar G, Wilson B, Kannoth Mukundan G, Divekar K, Jenita JL. Nanomedicine for Treating Major Brain Diseases: Advances and Future Directions. Molecular Pharmaceutics. 2025;22(8):4413-4434. doi:10.1021/acs.molpharmaceut.5c00277

BibTeX
@article{Sagar2025,
  author = {Sagar, Girisha and Wilson, Barnabas and Kannoth Mukundan, Geetha and Divekar, Kalpana and Jenita, Josephine Leno},
  title = {Nanomedicine for Treating Major Brain Diseases: Advances and Future Directions},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {8},
  pages = {4413--4434},
  doi = {10.1021/acs.molpharmaceut.5c00277}
}
Kostenlos starten →